New Data Demonstrate Efficacy, Value of Smith & Nephew Advanced Wound
Management Portfolio
ST. PETERSBURG, Fla., Oct. 22 /PRNewswire-FirstCall/ -- The Advanced Wound
Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew
Plc (LSE: SN; NYSE: SNN), announced today that clinicians will present a total
of 20 clinical posters featuring its Negative Pressure Wound Therapy (NPWT)
Systems and ALLEVYN(TM) AG, ALLEVYN AG Gentle, ACTICOAT(TM) and IODOSORB(TM)
advanced wound dressings during the 24th Annual Clinical Symposium on Advances
in Skin and Wound Care's poster session. The poster session opens at 10:30am
CT on October 23, 2009.
"We look forward to the presentation of such a large body of new data
associated with our advanced wound management products," said Tom Dugan, North
American President, Smith & Nephew Advanced Wound Management. "We are
particularly excited to see the results of a large, prospective multi-center
study of gauze-based NPWT on grafted and non-grafted patients. Smith & Nephew
is committed to helping clinicians at every stage of wound treatment deliver
the best possible care and deliver value to their healthcare institutions. We
are delighted that so many clinicians are advancing new research with the aid
of our comprehensive platform for the preparation, protection and progression
towards healing of wounds."
The body of new data on display at the Symposium includes the following
posters:
-- A Prospective Multi-Centre Clinical Evaluation of Gauze-Based Negative
Pressure Wound Therapy: Results from 131 patients, Dr. Raymond M.
Dunn,
et al.
-- Negative Pressure Wound Therapy as a Dressing for Split-Thickness Skin
Grafts: Our Experience, Dr. Julie O'Brien et al.
-- A Novel Dressing Technique for the Management of Highly Exudating
Lower
Extremity Wounds Utilizing Gauze-based Negative Pressure Wound
Therapy,
Penny Campbell, John Cockwill.
-- A Prospective, Open, Multi-Centre Study to Evaluate the Functionality
and Device Performance of a New Portable Negative Pressure Wound
Therapy
System in the Management of Acute and Chronic Wounds, Dr. Don Hudson
and
Dr. Kevin Adams.
-- A Case Report of Successful Limb Salvage with a new Negative Pressure
Wound Therapy System, Dr. Pasquale Cancilliere.
-- A Prospective, Non-Comparative, Clinical Evaluation to Determine the
Effect of a New Non-Adhesive Absorbent 3-Layer Silver Barrier Dressing
on the Reduction of Bioburden and Closure of Venous Leg Ulcers, Dr.
John
Lantis and Cindy Gendics, RN, CCRA.
Smith & Nephew will present the comprehensive portfolio of advanced wound
management products reflected in these clinical posters at Booth 111.
Featured products include the RENASYS(TM) EZ and RENASYS(TM) GO Systems, and
the ALLEVYN(TM) and ACTICOAT(TM) portfolios.
"The interactive booth is designed with hands-on product demonstration and
training stations to enhance the customer experience," stated Ian Dawson,
North American Vice President of Marketing. "Customers will be able to gain
hands-on experience with the foam and gauze interfaces that are available with
the RENASYS System. The versatility of the RENASYS systems allows clinicians
to make their own choice to use gauze and foam wound interfaces based on the
individual needs of the patient, confident that either approach will meet
their clinical objectives for NPWT."
The Right Dressing for the Right Wound
The full-range ALLEVYN portfolio offers triple action technology for fluid
handling capabilities, absorption, retention and transpiration. The ALLEVYN
Ag line offers bactericidal levels of silver with absorption capability, while
the ALLEVYN Gentle range was developed to address the needs of fragile skin.
Smith & Nephew is the only company to offer a combination of antimicrobial
capability and gentle adhesive technology in the ALLEVYN Ag Gentle Border
Dressing. ALLEVYN Adhesive is available for high friction areas and ALLEVYN
Non-Adhesive for compromised skin.
ACTICOAT is a trusted first line antimicrobial intervention to help prevent
and manage life threatening infections in a range of dressing types. The
ACTICOAT portfolio presentation will focus on the recently introduced ACTICOAT
Flex line, which provides flexible conformability for anatomical areas such as
face and hands and breakthrough stretch properties to improve patient comfort
during wear.
The Symposium is being held at the Henry B. Gonzalez Convention Center in San
Antonio, Texas, from October 22 to 25, 2009.
For more information about Smith & Nephew, please go to www.smith-nephew.com.
Product-specific information is available at www.myrenasys.com,
www.allevyn.com, www.iodosorb.com, and www.acticoat.com.
About Smith & Nephew
Smith & Nephew is a global medical technology business, specializing in
Orthopeadics, including Reconstruction, Trauma and Clinical Therapies,
Endoscopy and Advanced Wound Management. Smith & Nephew is a global leader in
arthroscopy and advanced wound management and is one of the leading global
orthopeadics companies.
Smith & Nephew is dedicated to helping improve people's lives. The Company
prides itself on the strength of its relationships with its surgeons and
professional healthcare customers, with whom its name is synonymous with high
standards of performance, innovation and trust. The Company operates in 32
countries around the world. Annual sales in 2008 were nearly $3.8 billion.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the
meaning of the US Private Securities Litigation Reform Act of 1995. In
particular, statements regarding expected revenue growth and trading margins
discussed under "Outlook" are forward-looking statements as are discussions of
our product pipeline. These statements, as well as the phrases "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate", "expect",
"target", "consider" and similar expressions, are generally intended to
identify forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties and other important factors (including,
but not limited to, the outcome of litigation, claims and regulatory
approvals) that could cause the actual results, performance or achievements of
Smith & Nephew, or industry results, to differ materially from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Please refer to the documents that Smith & Nephew
has filed with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith & Nephew's most
recent annual report on Form 20F, for a discussion of certain of these
factors.
All forward-looking statements in this press release are based on information
available to Smith & Nephew as of the date hereof. All written or oral
forward-looking statements attributable to Smith & Nephew or any person acting
on behalf of Smith & Nephew are expressly qualified in their entirety by the
foregoing. Smith & Nephew does not undertake any obligation to update or
revise any forward-looking statement contained herein to reflect any change in
Smith & Nephew's expectation with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.
SOURCE Smith & Nephew
Press: Steve DiMattia, Managing Director of EVC Group, Inc., +1-646-201-5445,
for Smith & Nephew; Other Inquiries: Tom Dugan, North American President of
Smith & Nephew Advanced Wound Management, +1-727-399-3766; Investors: Liz
Hewitt, Group Director, Corporate Affairs of Smith & Nephew, + 44 (0)
207-401-7646
